Provided herein are methods of treating or preventing cancer in a subject in need thereof, the methods comprise administering to the subject in need thereof (a) one or more nucleic acids encoding an elephant p53 protein, an elephant LIF protein, and/or combinations thereof, or (b) one or more elephant p53 proteins, elephant LIF proteins, and/or combinations thereof. Also provided are pharmaceutical compositions comprising a pharmaceutically acceptable carrier and (a) one or more nucleic acids encoding an elephant p53 protein, an elephant LIF protein, and/or combinations thereof, or (b) one or more elephant p53 proteins, elephant LIF proteins, and/or combinations thereof.

Provided herein are highly-characterized isolated exosomes, methods to produce such exosomes, and methods for the use of such exosomes in treating diseases such as neurodegenerative diseases.

Provided herein are highly-characterized isolated exosomes, methods to produce such exosomes, and methods for the use of such exosomes in treating diseases such as neurodegenerative diseases.

Methods of disrupting germ cell migration and development in a fish embryo by inducing targeted expression of Sdf-1a or Lif and disruption of the Sdf-1a gradient or a Lif signaling pathway in the fish embryo have been developed. Plasmid constructs containing a gene encoding Sdf-1a or Lif and a gene encoding a signaling sequence for targeted expression of Sdf-1a or Lif have been generated. The plasmids will be administered to a fish or a population of fish to reproductively sterilize the population with efficacy of up to 100%. Transgenic fish of this invention are reproductively incompetent of genetically contaminating a wild fish population.

The present disclosure relates to a three-dimensional micro-environment structure for controlling cell behavior, a three-dimensional surface and an array for controlling cell behavior, and a method for manufacturing the three-dimensional micro-environment structure.

In some aspects, the disclosure relates to compositions and methods useful for maintaining or improving retinal function and/or morphology. The disclosure is based, in part, on isolated nucleic acids encoding certain neurotrophic factors (e.g., leukemia inhibitory factor (LIF), etc.) and gene therapy vectors (e.g., recombinant adeno-associated virus (rAAV) vectors) encoding the same. In some embodiments, isolated nucleic acids and gene therapy vectors described by the disclosure are useful for treatment of certain diseases or disorders of the eye, for example retinal degeneration, retinitis pigmentosa (RP), age-related macular degeneration (AMD), glaucoma, etc.

In some aspects, the disclosure relates to compositions and methods useful for maintaining or improving retinal function and/or morphology. The disclosure is based, in part, on isolated nucleic acids encoding certain neurotrophic factors (e.g., leukemia inhibitory factor (LIF), etc.) and gene therapy vectors (e.g., recombinant adeno-associated virus (rAAV) vectors) encoding the same. In some embodiments, isolated nucleic acids and gene therapy vectors described by the disclosure are useful for treatment of certain diseases or disorders of the eye, for example retinal degeneration, retinitis pigmentosa (RP), age-related macular degeneration (AMD), glaucoma, etc.